Inhibition potential of natural flavonoids against selected omicron (B.1.19) mutations in the spike receptor binding domain of SARS-CoV-2: a molecular modeling approach

J Biomol Struct Dyn. 2025 Feb;43(2):1068-1082. doi: 10.1080/07391102.2023.2291165. Epub 2023 Dec 19.

Abstract

The omicron (B.1.19) variant of contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered a variant of concern (VOC) due to its increased transmissibility and highly infectious nature. The spike receptor-binding domain (RBD) is a hotspot of mutations and is regarded as a prominent target for screening drug candidates owing to its crucial role in viral entry and immune evasion. To date, no effective therapy or antivirals have been reported; therefore, there is an urgent need for rapid screening of antivirals. An extensive molecular modelling study has been performed with the primary goal to assess the inhibition potential of natural flavonoids as inhibitors against RBD from a manually curated library. Out of 40 natural flavonoids, five natural flavonoids, namely tomentin A (-8.7 kcal/mol), tomentin C (-8.6 kcal/mol), hyperoside (-8.4 kcal/mol), catechin gallate (-8.3 kcal/mol), and corylifol A (-8.2 kcal/mol), have been considered as the top-ranked compounds based on their binding affinity and molecular interaction profiling. The state-of-the-art molecular dynamics (MD) simulations of these top-ranked compounds in complex with RBD exhibited stable dynamics and structural compactness patterns on 200 nanoseconds. Additionally, complexes of these molecules demonstrated favorable free binding energies and affirmed the docking and simulation results. Moreover, the post-simulation validation of these interacted flavonoids using principal component analysis (PCA) revealed stable interaction patterns with RBD. The integrated results suggest that tomentin A, tomentin C, hyperoside, catechin gallate, and corylifol A might be effective against the emerging variants of SARS-CoV-2 and should be further evaluated using in-vitro and in-vivo experiments.Communicated by Ramaswamy H. Sarma.

Keywords: SARS-CoV-2; molecular dynamics (MD) simulations; natural flavonoids; omicron (B.1.19); receptor binding domain (RBD).

MeSH terms

  • Antiviral Agents* / chemistry
  • Antiviral Agents* / pharmacology
  • Binding Sites
  • COVID-19 / virology
  • COVID-19 Drug Treatment
  • Catechin / analogs & derivatives
  • Catechin / chemistry
  • Catechin / pharmacology
  • Flavonoids* / chemistry
  • Flavonoids* / pharmacology
  • Humans
  • Molecular Docking Simulation*
  • Molecular Dynamics Simulation*
  • Mutation*
  • Protein Binding*
  • SARS-CoV-2* / drug effects
  • SARS-CoV-2* / genetics
  • Spike Glycoprotein, Coronavirus* / antagonists & inhibitors
  • Spike Glycoprotein, Coronavirus* / chemistry
  • Spike Glycoprotein, Coronavirus* / genetics
  • Spike Glycoprotein, Coronavirus* / metabolism

Substances

  • Flavonoids
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Antiviral Agents
  • Catechin

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported by awards from the Canadian Institutes of Health Research (CIHR), the Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding initiative [CIHR OV2–170357], Mpox Rapid Research Funding initiative (CIHR MZ1 187236), Research Nova Scotia (DJK), Atlantic Genome/Genome Canada (DJK), Li-Ka Shing Foundation (DJK), and Dalhousie Medical Research Foundation (DJK). DJK is the Canada Research Chair in Translational Vaccinology and Inflammation.